Selective HDAC6 Inhibition By GB-1101 Revokes Tumor Immune Privilege and Synergizes with Immune Checkpoint Therapies to…
April 28, 2022
The Thing About Theranostics…
The landscape of oncology drug development is rapidly evolving, with personalized medicine taking center stage. At the heart of this revolution is ...
American Association of Pharmaceutical Scientists (AAPS) Flow Cytometry Action Programming Committee
By Jennifer J. Stewart, PhD
Why Small Molecules Are Still a Big Deal
In the biotech world, small molecules often get treated like the veteran actor at the awards show – respected, but no longer the star of the night. ...
Get Started
Contact Us Today!
If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.